1. Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20(1):67–76.
2. Annemans L, Aymé S, Le Cam Y, Facey K, Gunther P, Nicod E, Reni M, Roux J-L, Schlander M, Taylor D. Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50.
3. Bignami F. Eurordis survey on orphan drugs availability in Europe. Barcelona: 6th eurordis round table of companies workshop; 2007.
4. Le Cam, Y., 2011. Inventory of access and prices of orphan drugs across Europe.
https://img2.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_YLeCam_Final.pdf
. Last accessed 17 Sep 2011.
5. de Varax A, Letellier M, Börtlein G. Study on orphan drugs: phase I: overview of the conditions for marketing orphan drugs in Europe. Paris: Alcimed; 2015. p. 2004.